CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC 50 of 8.1 nM for EP300 HAT . CPI-1612 has an anticancer activity In Vitro CPI-1612 inhibits full length EP300 and full length CBP with IC 50 values In Vivo CPI-1612 (compound 17; 0.5 mg/kg; oral administration; twice a day; for 4 weeks) treatment shows 67% tumor growth inhibition (TGI) with concomitant reduction of H3K27Ac in plasma and reduction of H3K18Ac in the tumor . ?\nWhile the oral exposure of CPI-1612 (compound 17) in dogs (0.5 mg/kg IV; 1.0 mg/kg PO; clearance = 0.42 L/h/kg, V ss = 3.7 L/kg, T 1/2 = 5.5 h, F% = 71; AUC/dose = 1691 h·mg/mL) and mice (1 mg/kg IV; 5 mg/kg PO; clearance = 3.8 L/h/kg, V ss = 2.0 L/kg, T 1/2 = 0.98 h, F% = 79; AUC/dose = 211 h·mg/mL) is good, the exposure in rats is limited by poor bioavailability (1.0 mg/kg IV; 5.0 mg/kg PO; clearance = 2.6 L/h/kg, V ss = 1.8 L/kg, T 1/2 = 1.2 h, F% = 9; AUC/dose = 35.6 h·mg/mL) . ?\nA single dose of CPI-1612 is administered orally to CD-1 mice and brain and plasma exposures of CPI-1612 are measured at 0.25, 0.5, 1.0, 2.0, 4.0, and 8.0 h. CPI-1612 is highly brain-penetrant, showing a brain-to-plasma ratio of 0.35 after a single oral dose . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57B6 mice injected with JEKO-1 cells Dosage: 0.5 mg/kg Administration: Oral administration; twice a day; for 4 weeks Result: Showed 67% tumor growth inhibition (TGI) at a dose of 0.5 mg/kg. Form:Solid IC50& Target:CBP/p300